Category Archives: Hepatitis C care & treatment
FDA approves the first genotype test for hepatitis C
In June 2013, the US Food & Drug Administration (FDA) approved the first test for detecting the various genotypes of hepatitis C. This blood/serum test should only be used for those diagnosed with chronic hepatitis C, and not for routine screening of the virus. The Abbott…Read More
In an article published in the Journal of the American Medical Association, the new 2-drug regimen of sofosbuvir + ribavirin cured a little more than 2/3 of patients with difficult-to-treat hepatitis C. Characteristics in this study that related to being “difficult to treat” included having genotype…Read More
Project Inform holds annual Think Tank on scaling up risk-based hepatitis C screening
On September 17 and 18, 2013, Project Inform will convene a Think Tank focusing on hepatitis C: “Scaling-Up Risk-Based Hepatitis C Screening in the United States”. Hosting 30 national, state and local health officials, policy experts, doctors and community advocates, Project Inform will utilize the Think…Read More
by Mark Mascolini, National AIDS Treatment Advocacy Project 7th International AIDS Society Conference, Kuala Lumpur, June 2013: Every year 1 in 5 middle-aged or older gay men in an Australian cohort became infected with a human papillomavirus (HPV) genotype covered by the currently available quadrivalent HPV…Read More
7th International AIDS Society Conference, Kuala Lumpur, June 2013: Results from a study in London shows a high rate of re-infection with hepatitis C (HCV) in 858 gay men living with HIV. A total of 145 men were followed who had a documented date of an…Read More
Project Inform applauds the U.S. Preventive Services Task Force (USPSTF) for making a significant change in the release of its updated hepatitis C screening recommendations to test all people born between 1945 and 1965, as well as those who are at risk of infection. In August…Read More
On Friday, June 7, the maker of the experimental drug sofosbuvir announced that the drug had been given priority review status by the FDA. The FDA grants this status to drug candidates that may offer major advances in treatment over existing options. In clinical studies, some…Read More